p.89 抽出テキスト

224. Timpka S, Fraser A, Schyman T, Stuart JJ, Åsvold BO, Mogren I, et al. The value of pregnancy complication history for 10-year cardiovascular disease risk prediction in middle-aged women. Eur J Epidemiol 2018;33:1003–10. https://doi.org/10.1007/ s10654-018-0429-1 225. Blankenberg S, Salomaa V, Makarova N, Ojeda F, Wild P, Lackner KJ, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J 2016;37:2428–37. https://doi.org/10.1093/eurheartj/ehw172 226. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, et al. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM biomarker project Scottish cohort. Eur Heart J 2014;35:271–81. https://doi.org/10.1093/eurheartj/eht406 227. Schoenthaler AM, Lancaster KJ, Chaplin W, Butler M, Forsyth J, Ogedegbe G, et al. Cluster randomized clinical trial of FAITH (faith-based approaches in the treatment of hypertension) in blacks. Circ Cardiovasc Qual Outcomes 2018;11:e004691. https:// doi.org/10.1161/circoutcomes.118.004691 228. Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al. May Measurement Month 2019: the global blood pressure screening campaign of the international society of Hypertension. Hypertension 2020;76:333–41. https://doi.org/10. 1161/hypertensionaha.120.14874 229. Victor RG, Lynch K, Li N, Blyler C, Muhammad E, Handler J, et al. A cluster-randomized trial of blood-pressure reduction in black barbershops. N Engl J Med 2018;378: 1291–301. https://doi.org/10.1056/NEJMoa1717250 230. Sun Y, Mu J, Wang DW, Ouyang N, Xing L, Guo X, et al. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet 2022;399:1964–75. https://doi.org/10.1016/s0140-6736(22)00325-7 231. Schmidt BM, Durao S, Toews I, Bavuma CM, Hohlfeld A, Nury E, et al. Screening strategies for hypertension. Cochrane Database Syst Rev 2020;5:CD013212. https://doi.org/ 10.1002/14651858.CD013212.pub2 232. Kaczorowski J, Chambers LW, Dolovich L, Paterson JM, Karwalajtys T, Gierman T, et al. Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP). BMJ 2011;342: d442. https://doi.org/10.1136/bmj.d442 233. Lindholt JS, Søgaard R, Rasmussen LM, Mejldal A, Lambrechtsen J, Steffensen FH, et al. Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial. N Engl J Med 2022;387:1385–94. https://doi.org/10.1056/NEJMoa2208681 234. Sheppard JP, Schwartz CL, Tucker KL, McManus RJ. Modern management and diagnosis of hypertension in the United Kingdom: home care and self-care. Ann Glob Health 2016;82:274–87. https://doi.org/10.1016/j.aogh.2016.02.005 235. Andersson H, Hedström L, Bergman S, Bergh H. The outcome of two-step blood pressure screening in dental healthcare. Scand J Public Health 2018;46:623–9. https://doi. org/10.1177/1403494818759840 236. Zhang H, Thijs L, Kuznetsova T, Fagard RH, Li X, Staessen JA. Progression to hypertension in the non-hypertensive participants in the Flemish study on environment, genes and health outcomes. J Hypertens 2006;24:1719–27. https://doi.org/10.1097/ 01.hjh.0000242395.07473.92 237. Conen D, Aeschbacher S, Thijs L, Li Y, Boggia J, Asayama K, et al. Age-specific differences between conventional and ambulatory daytime blood pressure values. Hypertension 2014;64:1073–9. https://doi.org/10.1161/hypertensionaha.114.03957 238. Karnjanapiboonwong A, Anothaisintawee T, Chaikledkaew U, Dejthevaporn C, Attia J, Thakkinstian A. Diagnostic performance of clinic and home blood pressure measurements compared with ambulatory blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2020;20:491. https://doi.org/10.1186/s12872- 020-01736-2 239. Viera AJ, Yano Y, Lin FC, Simel DL, Yun J, Dave G, et al. Does this adult patient have hypertension?: The rational clinical examination systematic review. JAMA 2021;326: 339–47. https://doi.org/10.1001/jama.2021.4533 240. Green BB, Anderson ML, Cook AJ, Ehrlich K, Hall YN, Hsu C, et al. Clinic, home, and kiosk blood pressure measurements for diagnosing hypertension: a randomized diagnostic study. J Gen Intern Med 2022;37:2948–56. https://doi.org/10.1007/s11606-022- 07400-z 241. Kim JS, Rhee MY, Kim CH, Kim YR, Do U, Kim J-H, et al. Algorithm for diagnosing hypertension using out-of-office blood pressure measurements. J Clin Hypertens (Greenwich) 2021;23:1965–74. https://doi.org/10.1111/jch.14382 242. van den Born BH, Lip GYH, Brguljan-Hitij J, Cremer A, Segura J, Morales E, et al. ESC Council on Hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother 2019;5:37–46. https://doi.org/10. 1093/ehjcvp/pvy032 243. Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. J Hum Hypertens 2004;18:607–13. https://doi.org/10. 1038/sj.jhh.1001721 244. Hagger MS, Koch S, Chatzisarantis NLD, Orbell S. The common sense model of selfregulation: meta-analysis and test of a process model. Psychol Bull 2017;143:1117–54. https://doi.org/10.1037/bul0000118 245. Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: the example of hypertension. Health Psychol 1985;4:115–35. https://doi.org/10.1037// 0278-6133.4.2.115 246. O’Carroll RE, Chambers JA, Dennis M, Sudlow C, Johnston M. Improving adherence to medication in stroke survivors: a pilot randomised controlled trial. Ann Behav Med 2013;46:358–68. https://doi.org/10.1007/s12160-013-9515-5 247. Hollands GJ, Usher-Smith JA, Hasan R, Alexander F, Clarke N, Griffin SJ. Visualising health risks with medical imaging for changing recipients’ health behaviours and risk factors: systematic review with meta-analysis. PLoS Med 2022;19:e1003920. https:// doi.org/10.1371/journal.pmed.1003920 248. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006;19:1190–6. https://doi.org/10.1016/j. amjhyper.2006.04.006 249. Parati G, Goncalves A, Soergel D, Bruno RM, Caiani EG, Gerdts E. New perspectives for hypertension management: progress in methodological and technological developments. Eur J Prev Cardiol 2023;30:48–60. https://doi.org/10.1093/eurjpc/zwac203 250. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012;125:882–7.e1. https://doi.org/ 10.1016/j.amjmed.2011.12.013 251. Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension 2019;74:1324–32. https://doi.org/10.1161/hypertensionaha. 119.13616 252. Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström K, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 2013;69:1955–64. https://doi.org/10.1007/s00228-013-1555-z 253. Burnier M, Egan BM. Adherence in hypertension. Circ Res 2019;124:1124–40. https:// doi.org/10.1161/circresaha.118.313220 254. Curneen JMG, Rabbitt L, Browne D, O’Donoghue DF, Alansari Y, Harhen B, et al. Major disparities in patient-reported adherence compared to objective assessment of adherence using mass spectrometry: a prospective study in a tertiary-referral hypertension clinic. Br J Clin Pharmacol 2022;89:1948–55. https://doi.org/10.1111/bcp.15292 255. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011;29: 610–8. https://doi.org/10.1097/HJH.0b013e328342ca97 256. Kim S, Shin DW, Yun JM, Hwang Y, Park SK, Ko Y-J, et al. Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension 2016;67:506–12. https://doi.org/ 10.1161/hypertensionaha.115.06731 257. Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension 2022;79:12–23. https://doi.org/10.1161/hypertensionaha.121.17596 258. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ 2012;345:e3953. https://doi.org/ 10.1136/bmj.e3953 259. Schoenthaler A, Knafl GJ, Fiscella K, Ogedegbe G. Addressing the social needs of hypertensive patients: the role of patient–provider communication as a predictor of medication adherence. Circ Cardiovasc Qual Outcomes 2017;10:e003659. https://doi. org/10.1161/circoutcomes.117.003659 260. Schmieder RE, Wassmann S, Predel HG, Weisser B, Blettenberg J, Gillessen A, et al. Improved persistence to medication, decreased cardiovascular events and reduced allcause mortality in hypertensive patients with use of single-pill combinations: results from the START-study. Hypertension 2023;80:1127–35. https://doi.org/10.1161/ hypertensionaha.122.20810 261. Ruzicka M, Leenen FHH, Ramsay T, Bugeja A, Edwards C, McCormick B, et al. Use of directly observed therapy to assess treatment adherence in patients with apparent treatment-resistant hypertension. JAMA Intern Med 2019;179:1433–4. https://doi. org/10.1001/jamainternmed.2019.1455 262. Pio-Abreu A, Trani-Ferreira F, Silva GV, Bortolotto LA, Drager LF. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart 2022;108:1952–6. https://doi.org/10.1136/heartjnl-2022-320802 263. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014;100:855–61. https://doi.org/10.1136/heartjnl-2013-305063 264. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046–52. https://doi.org/10.1001/archinte.162.18.2046 265. Näslund U, Ng N, Lundgren A, Fhärm E, Grönlund C, Johansson H, et al. Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet 2019;393: 133–42. https://doi.org/10.1016/s0140-6736(18)32818-6 266. Bengtsson A, Norberg M, Ng N, Carlberg B, Grönlund C, Hultdin J, et al. The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: results from the VIPVIZA randomized clinical trial. Am J Prev Cardiol 2021;7:100199. https://doi. org/10.1016/j.ajpc.2021.100199 267. Sjölander M, Carlberg B, Norberg M, Näslund U, Ng N. Prescription of lipid-lowering and antihypertensive drugs following pictorial information about subclinical Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026